| Patents for C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676) |
|---|
| 05/31/2006 | CN1257876C Lubricating oil composition |
| 05/30/2006 | US7053234 Antibacterial agents |
| 05/30/2006 | US7053212 Subtype selectivity; cyclohexanecarboxylic acid (4-hydroxy-benzyl)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amide for example; treating estrogen-related disorders such as sexual disorders, bone disorders; reduction of tamoxifen uterotropic effect |
| 05/30/2006 | US7053117 Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 05/30/2006 | US7053109 Aminediols for the treatment of Alzheimer's disease |
| 05/30/2006 | US7053105 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
| 05/30/2006 | US7053104 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| 05/30/2006 | US7053088 Vanilloid receptor ligands and their use in treatments |
| 05/30/2006 | US7053057 Caspase inhibitors and uses thereof |
| 05/26/2006 | WO2006055725A2 Substituted amino acids as protein tyrosine phosphatase inhibitors |
| 05/26/2006 | WO2006054912A1 Aryl(hetaryl)-3-aminomethyl-quinilone-2 derivatives in the form of no-synthetase i and cyclooxygenase-2 nhibitors, methods for the production thereof and compositions based thereon |
| 05/26/2006 | WO2006054317A1 Process for the preparation of novel amorphous montelukast sodium |
| 05/26/2006 | WO2006053785A1 Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality |
| 05/26/2006 | WO2006053781A1 Process of making crystalline aripiprazole |
| 05/26/2006 | WO2006053780A1 Crystalline aripiprazole solvates |
| 05/26/2006 | WO2006053748A1 Substituted [(phenylethanoyl)amino] benzamides and the use thereof in the treatment of inflammatory and cardio-vascular diseases |
| 05/26/2006 | CA2588776A1 Substituted amino carboxylic acids |
| 05/26/2006 | CA2588381A1 Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality |
| 05/26/2006 | CA2587511A1 Substituted [(phenylethanoyl)amino] benzamides and the use thereof in the treatment of inflammatory and cardio-vascular diseases |
| 05/25/2006 | US20060111375 Compound having tgfß inhibitory activity and medicinal composition containing the same |
| 05/25/2006 | US20060111368 Phosphodiesterase inhibitor |
| 05/25/2006 | US20060111344 Arylethanolamine beta2-adrenoreceptor agonist compounds |
| 05/25/2006 | US20060110787 Use of fluorine-18-labeled fluoroquinolone antibiotics for diagnosing and monitoring bacterial infection |
| 05/24/2006 | EP1659120A1 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
| 05/24/2006 | EP1659112A1 Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor |
| 05/24/2006 | DE10347386B4 Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer Tetrahydronaphthalene derivatives, processes for their preparation and their use as anti-inflammatories |
| 05/24/2006 | CN1777577A Antibacterial agents |
| 05/24/2006 | CN1775759A Bicyclic androgen and progesterone receptor modulator compounds and methods |
| 05/24/2006 | CN1257160C Aimoquinoline and aminopyridine derivatives and their use as adenosine A3 ligands |
| 05/24/2006 | CN1256998C Sublimation purifying method and apparatus |
| 05/23/2006 | US7049378 Polymerization of olefin |
| 05/23/2006 | US7049325 Quinoline derivatives as anti-inflammatory agents |
| 05/23/2006 | US7049324 antitumor agents |
| 05/23/2006 | US7049309 Administering a therapeutically effective amount of 3-thia-4-(2-oxy/hydroxyphenyl)quinolin-2-one derivative to a patient to treat erectile dysfunction or irritable bowel syndrome |
| 05/18/2006 | WO2006051704A1 Imine compound |
| 05/18/2006 | WO2006051489A1 Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
| 05/18/2006 | WO2006051341A1 Isotopically marked quinoline derivatives as adenosin a3 receptor ligands |
| 05/18/2006 | WO2006050992A1 Compounds having activity at nk3 receptor and uses thereof in medicine |
| 05/18/2006 | WO2006050991A1 Compounds having activity at nk3 receptor and uses thereof in medicine |
| 05/18/2006 | WO2006034480A3 Sulfonamide bicyclic compounds |
| 05/18/2006 | WO2005051301A3 Heterocyclic inhibitors of mek and methods of use thereof |
| 05/18/2006 | US20060106256 e.g. 1-[(benzylamino)methyl]-3-(3,5-difluorophenyl)-2-({3-[(dipropylamino)carbonyl]benzoyl}amino)propyl 4-nitrophenyl carbonate; secretase inhibitors; neurodegenerative disorders; Alzheimer's, Parkinson's diseases, Down syndrom, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type |
| 05/18/2006 | US20060106233 Process for the preparation of disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups |
| 05/18/2006 | US20060106061 PGD2 receptor antagonists for the treatment of inflammatory diseases |
| 05/18/2006 | US20060106058 Chemical compounds |
| 05/18/2006 | US20060105961 Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia |
| 05/18/2006 | DE102005048695A1 Preparation of aripiprazole useful to prepare 7-(4-halobutoxy)-3,4-dihydro-(1H)-quinolinone comprises reacting 7-hydroxy-3,4-dihydro-2(1H)-quinolinone with 1,4-disubstuted-butane followed by reacting with 1-(2,3-dichlorophenyl)piperazine |
| 05/18/2006 | DE102005048694A1 Preparation of 7-hydroxy-3,4-dihydroquinolinone useful as an intermediate in preparing aripiprazole for treating schizophrenia involves reacting N-(3-methoxyphenyl)-3-chloropropionamide with Lewis acid |
| 05/18/2006 | CA2588073A1 Isotopically marked quinoline derivatives as adenosin a3 receptor ligands |
| 05/18/2006 | CA2587667A1 Imine compound |
| 05/18/2006 | CA2586156A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 05/18/2006 | CA2585983A1 Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
| 05/17/2006 | EP1656348A1 Acetylene derivatives as inhibitors of histone deacetylase |
| 05/17/2006 | EP1656142A2 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
| 05/17/2006 | EP1377552B1 Metal complexes and therapeutic uses thereof |
| 05/17/2006 | EP1370532B1 Method for producing cyclopentadiene compounds |
| 05/17/2006 | EP1109787B1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 05/17/2006 | CN1774423A A process for the preparation of 5-(haloacetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones |
| 05/17/2006 | CN1772738A Crystalline Alipiprazole and its prepn |
| 05/17/2006 | CN1256328C Position seven substituted amine methyl fluoro quinolone derivative having antibacterial activity and its preparation method |
| 05/17/2006 | CN1256327C Process for the preparation of quinoline derivatives |
| 05/16/2006 | US7045627 Reacting chloroperbenzoic acid with 3-dichloromethylthio-7-fluoro-1-,ethyl-4-quinolone in dichloromethane; |
| 05/16/2006 | US7045626 Quinoline derivatives, process for preparing them and use for the treatment of diseases mediated by s-CD23 |
| 05/16/2006 | US7045625 Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates |
| 05/16/2006 | US7045533 Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout |
| 05/16/2006 | US7045518 Compounds for treatment of AIDS with enzyme inhibitors |
| 05/16/2006 | US7045514 Therapeutic heterocyclic compounds |
| 05/16/2006 | CA2242571C Amino compounds and angiotensin iv receptor agonists |
| 05/11/2006 | WO2006049968A1 Pyrimidine and quinoline potentiators of metabotropic glutamate receptors |
| 05/11/2006 | WO2006048146A1 Quinoline as allosteric enhancers of the gaba-b receptors |
| 05/11/2006 | US20060100436 Antimicrobial quinolones, their compositions, and uses |
| 05/11/2006 | US20060100239 Method for producing optically active amines |
| 05/11/2006 | US20060100202 Novel compounds |
| 05/11/2006 | CA2586066A1 Quinoline as allosteric enhancers of the gaba-b receptors |
| 05/11/2006 | CA2585210A1 Pyrimidine and quinoline potentiators of metabotropic glutamate receptors |
| 05/10/2006 | EP1655287A1 Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change |
| 05/10/2006 | EP1654260A2 6-menbered heteroaryl compounds for the treatment of neurodegenerative disorders |
| 05/10/2006 | EP1654232A1 Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides |
| 05/10/2006 | EP1654225A2 Melanin concentrating hormone receptor antagonists |
| 05/10/2006 | EP1654217A1 2- adamantyl derivatives as p2x7 receptor antagonists. |
| 05/10/2006 | EP1653967A2 Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia |
| 05/10/2006 | CN1771230A Process for the synthesis of 3-cyano-6-alkoxy-7-nitro-4-quinolones |
| 05/09/2006 | US7041839 Therapy for hormone sensitivity disease; side effect reduction; anticancer agents |
| 05/09/2006 | US7041829 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 05/09/2006 | US7041809 Metal complex dyes for inkjet inks |
| 05/09/2006 | US7041691 E.g., 2-(2,6-Dichloro-4-nitro-phenylsulfanyl)-benzothiazole-5-carboxylic acid methyl ester; modulators of peroxisome proliferator-activated receptors (PPARs) to treat type 11 diabetes and obesity; hypertension, hyperlipidemia, hypercholesterolemia, and hyperlipoproteinemia; antiinflammatory agents |
| 05/09/2006 | US7041690 Viricides; hepatitis virus infections |
| 05/09/2006 | US7041664 e.g., (S)-N-(1-phenylpropyl)-2-(pyrrolidin-1-yl)-quinoline-4-carboxamide in a container with instructions for treating anxiety, depression, schizophrenia, obesity, chronic pulmonary obstructive disorder, or pain |
| 05/04/2006 | WO2006047740A2 Heat shock protein 90 inhibitors |
| 05/04/2006 | WO2006047262A1 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury |
| 05/04/2006 | WO2006046916A1 Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| 05/04/2006 | WO2006046915A1 Use of unsaturated quionoline or naphtalene derivatives as medicaments |
| 05/04/2006 | WO2006046778A1 3-carbamoyl-2-pyridone derivative |
| 05/04/2006 | WO2006045416A1 Quinoline derivatives |
| 05/04/2006 | WO2006023231A3 Fluorescent metal ion indicators with large stokes shift |
| 05/04/2006 | WO2005073194A3 Solid forms of montelukast acid |
| 05/04/2006 | WO2005061475A3 Ornithine derivatives as prostaglandin e2 agonists or antagonists |
| 05/04/2006 | US20060094789 Alpha- and beta-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors |
| 05/04/2006 | US20060094755 Novel quinoline-based metal chelators as antiviral agents |
| 05/04/2006 | US20060094754 1-[4-(4-Chloro-phenyl)-2-methyl-6-trifluoromethoxy-quinolin-3-yl]-ethanone; Cyclopropyl-[4-(4-methanesulfonyl-phenyl)-2-methyl-6-morpholin-4-yl-quinolin-3-yl]-methanone; useful in the treatment of CNS disorders comprising anxiety and depression. |